Company Overview

Corporate Philosophy

Promoting Healthcare Innovation

Healthcare Innovation: our corporate philosophy in which health is the number-one priority; one in which Sato Pharmaceutical provides the products that answer the demand for a more positive, more enjoyable daily life.
 Keeping this in mind, we strive to realize selfcare by providing effective, safe, high-quality products.

1 Healthcare

Creating a positive environment around self-care

Sato’s technological strength and originality are highly rated, and shown through products including high-value-added switch OTC drugs that meet market changes; OTC pharmaceutical products aligned with consumer needs; quasi-drugs; supplements and cosmetics. Our main OTC pharmaceutical products, including Yunker, Acess, Stona, and Ringl IB, are supported by the media presence of top Japanese personalities including Ichiro Suzuki, Mao Asada, and Shunputei Shota.
 We also focus on management support for retailers, inviting experts to join as we regularly hold the Sato Drugstore Conference and Sato Symposium. We are also moving proactively to create a positive environment for practicing selfcare through the OTC Self-Medication Promotion Foundation.

2 Ethical Pharmaceuticals

Developing highly original products and enhancing drug discovery research

Sato’s ethical pharmaceutical business provides unique products, particularly in dermatology, including the oral antifungal agent NAILIN Capsules 100mg, launched in July 2018; LUCONAC Solution 5%, a topical onychomycosis treatment; the topical anesthetic Emla Cream and Emla Patch; and Patch Test Panel (S), an allergic dermatitis test.
 These products were born out of a desire to make examination and treatment as comfortable as possible for patients, and apply the technologies and expertise accumulated by Sato over many years. Sato not only promotes the in-house development of new compounds, but also enters into partnerships with companies, universities and research institutes, both in Japan and overseas, for research in the field of drug discovery. We have also begun new joint research projects with the University of Tokyo and Juntendo University.

3 Global Strategy

Promoting the SATO brand in international markets

To help support the daily health of people around the world, Sato has developed six branches in the rapidly growing Asian region, North America and Europe. Sato conducts comprehensive marketing activities in each country and spreads awareness of the SATO brands by accurately grasping the needs of each country and region.
 In Asia, the center of our overseas business, the Yunker, Hakubi and Nazal brands are growing strongly. In North America, we are developing store brands in major drugstore chains, while in overseas Japanese and Asian markets we are expanding sales channels and actively promoting safe and reliable Japanese products, with a focus on Yunker.

4 Production Efficiency

An efficient production and distribution system, with concern for the environment

Our production centers in Japan and overseas provide a flexible, robust production system, supplying high-quality products quickly and stably.
 The Hachioji factory’s production line has been enhanced with the introduction of a high-speed line to ensure efficiency. At the Kazusa factory, a new production line was set up for external agents, with production beginning in October 2017. Our Taiwan factory became PIC/S-GMP compliant in 2014, with successful renewal in 2016. Here we have an advanced, world-class production system, now exporting to Asian countries.
 Our domestic distribution system uses a centrally controlled product information system for the network of five distribution centers. Sato is also using LED lighting, resource-saving systems, recycling and natural energy utilization and other initiatives to reduce environmental impact.